Drug intelligence / Profile preview

gramine

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Gramine is a natural indole alkaloid primarily extracted from plants such as *Arundo donax L.* (giant reed) and barley (*Hordeum vulgare*). It exhibits a wide range of pharmacological properties, including anti-inflammatory, antiviral, antioxidant, and potent anti-tumor activities. In the context of oncology, gramine has been shown to inhibit cell proliferation and migration, induce apoptosis, and trigger G0/G1 phase cell cycle arrest. Its primary mechanism of action in cervical cancer involves the downregulation of Cyclin-dependent kinase 2 (CDK2) by modulating a competitive endogenous RNA (ceRNA) axis consisting of the lncRNAs CYP4A22-AS1 and LINC00958, which act as molecular sponges for hsa-miR-133b. Additionally, gramine has been reported to suppress the PI3K/Akt/mTOR and JAK/STAT3 signaling pathways and modulate TGF-β signaling to inhibit tumor angiogenesis. Beyond its anti-cancer potential, it has also demonstrated protective effects in models of airway inflammation and asthma.

Other names
donaxine3-(dimethylaminomethyl)indoleN,N-dimethyl-1H-indole-3-methanamine
02

Targets

CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on gramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call